RGEN
Repligen Corporation
NASDAQ: RGEN · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$115.91
-3.35% today
Updated 2026-06-05
Market cap
$6.99B
P/E ratio
137.72
P/S ratio
8.36x
EPS (TTM)
$0.90
Dividend yield
—
52W range
$101 – $176
Volume
1.1M
Repligen Corporation (RGEN) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$115.91
12-Month target
$40.25
2030 Target
—
Intrinsic (DCF)
$155.38
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.7B | $0.8B | $0.6B | $0.6B | $0.7B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 6.73%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.